Non-small cell lung cancer is one of the most common types of malignances worldwide and
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …

The emergence of immune checkpoint inhibitors for the treatment of cancer has led to major
changes to the therapeutic landscape of lung cancer. Improvements in overall survival …

Immune checkpoint inhibition as a new treatment approach is undergoing extensive
investigation in non–small cell lung cancer (NSCLC) and other malignancies. Unlike …

Lung cancer is one of the most common cancers and the leading cause of cancer-related
deaths worldwide. Most of these patients with non-small cell lung cancer (NSCLC) present …

Lung cancer is the leading cause of cancer-related mortality worldwide. Treatment with
immunotherapy has made a significant impact on the outcomes for those patients suffering …

Second-line treatment options are limited for patients with advanced non–small-cell lung
cancer (NSCLC). Standard therapy includes the cytotoxic agents docetaxel and pemetrexed …

Monoclonal antibodies that target immune checkpoint proteins, so-called immune
checkpoint inhibitors, prevent tumor evasion of the immune system and are often effective in …

Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of
patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective …

Emerging evidence on the role of the antitumor activity of the immune system has generated
great interest in immunotherapy even for tumors that were historically considered as …

Cancer immunotherapy with immune checkpoint inhibitors (ICIs) has become a “game
changer” in the treatment of advanced non-small cell lung cancer (NSCLC). Its most …